Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP Block vs Ilioinguinal/Iliohypogastric Block for Inguinal Hernia Analgesia
NCT06812741Phase 3Completed
- Sponsor
- PNS Shifa
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by PNS Shifa. Primary endpoint: Mean duration of Postoperative Analgesia at 6 months. Started Feb 2024; status: completed.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06812741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812741.